IceCure First-Half 2026 Earnings: 45% Revenue Growth Comes With Wider Losses

IceCure Medical (Nasdaq: ICCM) reported first-half 2026 revenue of $1.818 million, up about 45% from $1.250 million a year earlier, while basic and diluted net loss per share narrowed to $3.17 from $3.59. Gross profit and gross margin improved, but higher research, sales, and administrative spending widened the operating and net losses. The U.S. active commercial installed base expanded about 70%, while financing activity helped lift cash to $12.034 million at June 30, 2026.

Core Financial Results

Revenue growth came from higher sales of both ProSense systems and disposable probes. Gross profit grew faster than revenue, lifting the gross margin by approximately 2.2 percentage points, but the additional gross profit was not enough to cover increased operating expenses.

The lower per-share loss contrasts with the larger net loss because the weighted-average share count rose to approximately 2.77 million from 1.94 million.

Business and Commercial Performance

IceCure attributed revenue growth to both new ProSense placements and increasing disposable probe sales. The disposable growth is important to the company’s commercial model because it indicates procedural utilization beyond the initial sale of a system, although IceCure did not disclose separate revenue figures for systems and probes.

The U.S. active commercial installed base grew approximately 70%. The company connected that expansion with increased physician adoption, higher procedure volumes, and more active customer accounts following FDA clearance. IceCure also continued expanding internationally, citing growing adoption in Brazil and other markets without providing country-level sales figures.

Commercial expansion is occurring alongside the FDA-approved post-marketing CHoICE Study. IceCure expects additional U.S. clinical sites to join as enrollment expands, with the study intended to support physician adoption, future reimbursement opportunities, and broader commercialization.

Growth Investments Widened Losses While Financing Supported Liquidity

Total research and development, sales and marketing, and general and administrative expenses rose to $9.219 million from $7.391 million. That approximately $1.828 million increase substantially exceeded the $199,000 increase in gross profit, causing the operating loss to widen by $1.629 million.

R&D expense increased about 27% to $4.279 million, mainly because of the initiation of the CHoICE Study and foreign-exchange effects on payroll-related costs. Sales and marketing expense rose about 17% to $2.518 million as IceCure expanded its sales team, particularly in the United States. General and administrative expense increased about 30% to $2.422 million because of foreign-exchange effects and higher non-cash share-based compensation.

The company used $8.148 million of cash in operating activities, compared with $6.850 million a year earlier. Despite that higher operating cash use, cash and cash equivalents increased to $12.034 million from $8.897 million at the end of 2025, supported by $11.319 million of net financing cash flow during the first half.

That financing also increased the outstanding share count. IceCure had approximately 3.43 million shares outstanding at June 30, 2026, compared with 2.44 million at December 31, 2025, an increase of about 40%.

Management’s View

Chief Executive Officer Eyal Shamir described IceCure’s clinical and commercial activities as mutually reinforcing. In management’s view, increasing adoption can generate more clinical evidence and recurring disposable use, while clinical activity can improve physician confidence and support future reimbursement opportunities.

Management plans to continue investing in the U.S. commercial organization and the CHoICE Study. The company did not provide quantitative revenue, earnings, or cash-flow guidance with the results.

Risks Investors Should Watch

• Operating losses and cash consumption: Revenue and gross profit increased, but they remained small relative to operating expenses. Operating cash use also rose by about 19%.
• Commercialization costs: Expansion of the U.S. sales organization is increasing expenses before the company has demonstrated that revenue growth can offset the added cost base.
• Financing and dilution: The cash balance improved because of financing rather than positive operating cash flow, while shares outstanding increased materially from the end of 2025.
• Utilization and reimbursement execution: The commercial model depends not only on new ProSense placements but also on recurring disposable probe use. The CHoICE Study is intended to support adoption and future reimbursement, but those benefits have not yet been quantified.

Summary

IceCure’s first-half 2026 results showed progress in ProSense adoption, disposable utilization, and gross margin, led by a roughly 70% expansion of the U.S. active commercial installed base. However, clinical and commercial investments grew faster than gross profit, widening losses and operating cash use. The main issues to monitor are whether recurring probe sales can scale, whether the CHoICE Study advances adoption and reimbursement, and how the company balances continued investment with cash consumption and shareholder dilution.